Evaluation of vaccination herd immunity effects for anogenital warts in a low coverage setting with human papillomavirus vaccine-an interrupted time series analysis from 2005 to 2010 using health insurance data

BMC Infectious Diseases

Volumn 17, Issue 1, 2017, Pages

  Thöne, Kathrin ^a,b   Horn, Johannes ^c   Mikolajczyk, Rafael ^c,d,e  

^a LEIBNIZ INSTITUTE FOR PREVENTION RESEARCH AND EPIDEMIOLOGY BIPS   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Anogenital warts (AGWs); Herd immunity; Human papillomavirus (HPV) vaccine; Indirect vaccination effect; Vaccine coverage

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL EVALUATION; COHORT ANALYSIS; CONDYLOMA ACUMINATUM; DRUG EFFECT; FEMALE; HEALTH INSURANCE; HERD IMMUNITY; HUMAN; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; TIME SERIES ANALYSIS; TREND STUDY; VACCINATION; CONDYLOMATA ACUMINATA; GERMANY; IMMUNOLOGY; INCIDENCE; PAPILLOMAVIRUS INFECTIONS; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; CONDYLOMATA ACUMINATA; FEMALE; GERMANY; HUMANS; IMMUNITY, HERD; INCIDENCE; INSURANCE, HEALTH; INTERRUPTED TIME SERIES ANALYSIS; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RETROSPECTIVE STUDIES; VACCINATION; YOUNG ADULT;

EID: 85027276022     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-017-2663-7     Document Type: Article

References (36)

1. Gross G, Pfister H. Role of human papillomavirus in penile cancer, penile intraepithelial squamous cell neoplasias and in genital warts. Med Microbiol Immunol. 2004;193:35-44. doi: 10.1007/s00430-003-0181-2.
2. Baandrup L, Blomberg M, Dehlendorff C, Sand C, Andersen KK, Kjaer SK. Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis. 2013;40:130-5. doi: 10.1097/OLQ.0b013e31827bd66b.
3. Smith J, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121:621-32. doi: 10.1002/ijc.22527.
4. Schwabe U, Paffrath D. Arzneiverordnungsreport 2009. Aktuelle Daten, Kosten, Trends und Kommentare. Berlin Heidelberg: Springer-Verlag. 2009.
5. Harper DM, Franco EL, Wheeler CM, Moscicki A-B, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247-55.
6. FUTURE I/II Study Group, Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen O-E, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010;341:c3493.
7. Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis. 2011;11:39-44.
8. Blomberg M, Dehlendorff C, Munk C, Kjaer SK. Strongly decreased risk of genital warts after vaccination against human Papillomavirus: Nationwide follow-up of vaccinated and unvaccinated girls in Denmark. Clin Infect Dis. 2013;57:929-34. doi: 10.1093/cid/cit436.
9. Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw CS. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect. 2009;85:499-502. doi: 10.1136/sti.2009.037788.
10. Read TRH, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2011;87:544-7.
11. Ali H, Donovan B, Wand H, Read TRH, Regan DG, Grulich AE, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013;346:f2032. doi: 10.1136/bmj.f2032.
12. Leval A, Herweijer E, Arnheim-Dahlström L, Walum H, Frans E, Sparén P, et al. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis. 2012;206:860-6. doi: 10.1093/infdis/jis405.
13. Mikolajczyk RT, Kraut AA, Horn J, Schulze-Rath R, Garbe E. Changes in incidence of anogenital warts diagnoses after the introduction of human papillomavirus vaccination in Germany-an ecologic study. Sex Transm Dis. 2013;40:28-31. doi: 10.1097/OLQ.0b013e3182756efd.
14. Howell-Jones R, Soldan K, Wetten S, Mesher D, Williams T, Gill ON, et al. Declining genital warts in young women in england associated with HPV 16/18 vaccination: an ecological study. J Infect Dis. 2013;208:1397-403. doi: 10.1093/infdis/jit361.
15. Sandø N, Kofoed K, Zachariae C, Fouchard J. A reduced national incidence of anogenital warts in young danish men and women after introduction of a national quadrivalent human papillomavirus vaccination programme for young women - an ecological study. Acta Derm Venereol. 2014;94:288-92.
16. Bauer HM, Wright G, Chow J. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007-2010. Am J Public Health. 2012;102:833-5. doi: 10.2105/AJPH.2011.300465.
17. Perkins RB, Clark JA. What affects human Papillomavirus vaccination rates? A qualitative analysis of providers' perceptions. Womens Heal Issues. 2012;22(4):e379-86.
18. Wild F. Impfung gegen humane Papillomaviren (HPV); Eine Analyse der Verordnungsdaten Privatversicherer. 2011; WIP-Diskussionspapier 3/2011.
19. Bundeszentrale für gesundheitliche Aufklärung (BZgA). Elternbefragung zum Thema "Impfen im Kindesalter". http://www.bzga.de/forschung/studien-untersuchungen/studien/?sid=10. Accessed 16 Feb 2017.
20. Hense S, Hillebrand K, Horn J, Mikolajczyk R, Schulze-Rath R, Garbe E. HPV vaccine uptake after introduction of the vaccine in Germany: an analysis of administrative data. Hum Vaccines Immunother. 2014;10:1729-33.
21. Rieck T, Feig M, Deler Y, Wichmann O. Utilization of administrative data to assess the association of an adolescent health check-up with human papillomavirus vaccine uptake in Germany. Vaccine. 2014;32:5564-9.
22. Pigeot I, Ahrens W. Establishment of a pharmacoepidemiological database in Germany: methodological potential, scientific value and practical limitations. Pharmacoepidemiol Drug Saf. 2008;17:215-23. doi: 10.1002/pds.1545.
23. Ohlmeier C, Frick J, Prütz F, Lampert T, Ziese T, Mikolajczyk R, et al. Use of routine data from statutory health insurances for federal health monitoring purposes. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014;57:464-72.
24. Garbe E, Suling M, Kloss S, Lindemann C, Schmid U. Linkage of mother-baby pairs in the German Pharmacoepidemiological research database. Pharmacoepidemiol Drug Saf. 2011;20:258-64.
25. Daly LE. Confidence limits made easy: interval estimation using a substitution method. Am J Epidemiol. 1998;147:783-90.
26. Deleré Y, Böhmer MM, Walter D, Wichmann O. HPV vaccination coverage among women aged 18-20 years in Germany three years after recommendation of HPV vaccination for adolescent girls: results from a cross-sectional survey. Hum Vaccin Immunothe. 2013;9:1706-11.
27. Blödt S, Holmberg C, Müller-Nordhorn J, Rieckmann N. Human Papillomavirus awareness, knowledge and vaccine acceptance: a survey among 18-25 year old male and female vocational school students in Berlin, Germany. Eur J Pub Health. 2012;22:808-13.
28. Samkange-Zeeb F, Spallek L, Klug SJ, Zeeb H. HPV infection awareness and self-reported HPV vaccination coverage in female adolescent students in two German cities. J Community Health. 2012;37:1151-6.
29. Chow EP, Read TR, Wigan R, Donovan B, Chen MY, Bradshaw CS, Fairley CK. Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2015;91(3):214-9. doi: 10.1136/sextrans-2014-051813. Epub 2014 Oct 10.
30. Flagg EW, Schwartz R, Weinstock H. Prevalence of anogenital warts among participants in private health plans in the United States, 2003-2010: potential impact of human papillomavirus vaccination. Am J Public Health. 2013;103:1428-35.
31. Oliphant J, Perkins N. Impact of the human papillomavirus (HPV) vaccine on genital wart diagnoses at Auckland sexual health services. N Z Med J. 2011;124:51-8.
32. Drolet M, Bénard É, Boily M-C, Ali H, Baandrup L, Bauer H, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15:565-80. doi: 10.1016/S1473-3099(14)71073-4.
33. Widdice L, Ma Y, Jonte J, Farhat S, Breland D, Shiboski S, et al. Concordance and transmission of human papillomavirus within heterosexual couples observed over short intervals. J Infect Dis. 2013;207:1286-94.
34. Mercer CH, Aicken CRH, Tanton C, Estcourt CS, Brook MG, Keane F, et al. Serial monogamy and biologic concurrency: measurement of the gaps between sexual partners to inform targeted strategies. Am J Epidemiol. 2013;178:249-59.
35. Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, et al. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica vaccine and PATRICIA trials. Lancet Oncol. 2015;16:775-86. doi: 10.1016/S1470-2045(15)00047-9.
36. Robert-Koch-Institut. Impfquoten der Rotavirus-, Masern-, HPV-und Influenza- Impfung in Deutschland. Epidemiol Bull. 2017;1-16. https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2017/Ausgaben/01_17.pdf?__blob=publicationFile. Accessed 16 Feb 2017.